# XBiotech Inc.: Form 10-Q for the period ended Mar 31, 2023

- Company: [XBiotech Inc.](/companies/xbit.md) (CIK 1626878)
- Form: 10-Q
- Filed: 2023-05-10
- Accepted by EDGAR: May 10, 2023, 15:41 ET
- Period: 2023-03-31
- Accession: 0001171843-23-003144
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1626878/000117184323003144/xbit20230331_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1626878/000117184323003144/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-01-01 to 2023-03-31 | $0 | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months, 2023-01-01 to 2023-03-31 | $0 | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2023-01-01 to 2023-03-31 | $0 | us-gaap:GrossProfit |
| Research and development | 3 months, 2023-01-01 to 2023-03-31 | $6.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2023-01-01 to 2023-03-31 | −$7.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2023-01-01 to 2023-03-31 | −$37.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-01-01 to 2023-03-31 | −$3.8m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months, 2023-01-01 to 2023-03-31 | −$0.13 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 3 months, 2023-01-01 to 2023-03-31 | −$4.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2023-01-01 to 2023-03-31 | $6.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2023-03-31 | $152.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-03-31 | $216.3m | us-gaap:AssetsCurrent |
| Total assets | at 2023-03-31 | $242.1m | us-gaap:Assets |
| Current liabilities | at 2023-03-31 | $3.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-03-31 | $5.2m | us-gaap:Liabilities |
| Shareholders' equity | at 2023-03-31 | $236.9m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 15,791 characters.

**MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

### Overview

XBiotech Inc. (“XBiotech” or the “Company) is a pre-market biopharmaceutical company engaged in discovering and developing True Human™ monoclonal antibodies for treating a variety of diseases. True Human™ monoclonal antibodies are those which occur naturally in human beings—as opposed to being derived from animal immunization or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. XBiotech is focused on developing its True Human™ pipeline and manufacturing system.

Following the Janssen Transaction in December 2019, the tender offer in February 2020, and the dividends paid in July 2021, retained earnings as of March 31, 2023 were ($31.6) million. We had net losses of $3.8 million and $5.4 million for the three months ended March 31, 2023 and 2022, respectively. During the next year, we don’t expect any revenues. In addition, we expect to incur significant and increasing operating losses for the foreseeable future as we advance our drug candidates from discovery through preclinical testing and clinical. In addition to these increasing research and development expenses, we expect general and administrative costs to increase, particularly in consideration of current inflationary trends. We will need to generate significant revenues to achieve or sustain profitability, and we may never do so. As of March 31, 2023, we had 84 employees.

### Revenues

Prior to receiving payments under the clinical manufacturing agreement entered into in connection with the Janssen Transaction, we had not generated any revenue. Under the clinical manufacturing agreement, we manufacture bermekimab for use by Janssen in clinical trials, in exchange for fixed payments, paid in quarterly installments through 2021. In Febuary 2022, we entered a new manufacturing contract with a Janssen-related company whereby we continued to manufacture bermekimab through November 2022. The contract terminated in December 2022. Our ability to generate any additional revenue and/or to become profitable (or sustain any profitability) depends on our ability to successfully commercialize any product candidates we may advance in the future.

### Research and Development Expenses

Research and development expense consists of expenses incurred in connection with identifying and developing our drug candidates. These expenses consist primarily of salaries and related expenses, stock-based compensation, the purchase of equipment, laboratory and manufacturing supplies, facility costs, costs for preclinical and clinical research, development of quality control systems, quality assurance programs and manufacturing processes. We charge all research and development expenses to operating expenses as incurred.

The clinical development costs may further increase going forward with potentially more advanced studies in the future as we evaluate our clinical data and pipeline.

Clinical development timelines, likelihood of success and total costs vary widely. We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates. From inception through March 31, 2023, we have recorded total research and development expenses, including share-based compensation, of $285.3 million. Our total research and development expenses for the three months ended March 31, 2023 and 2022 were $6.2 million and $6.8 million, respectively. Share-based compensation accounted for $623 thousand and $990 thousand for the three months ended March 31, 2023 and 2022, respectively.

Research and development expenses, as a percentage of total operating expenses for the three months ended March 31, 2023 and 2022 were 87% and 84%, respectively. The percentages, excluding stock-based compensation, for the three months ended March 31, 2023 and 2022, were both 87%.

We will select drug candidates and research projects for further development on an ongoing basis in response to their preclinical and clinical success and commercial potential. For research and development candidates in early stages of development, it is premature to estimate when material net cash inflows from these projects might occur.

### General and Administrative Expenses

General and administrative expense consists primarily of salaries and related expenses for personnel in administrative, finance, business development and human resource functions, as well as the legal costs of pursuing patent protection of our intellectual property and patent filing and maintenance expenses, stock–based compensation, and professional fees for legal services. Our total general and administration expenses for the three months ended March 31, 2023 and 2022 were $0.9 million and $1.3 million, respectively. Share-based compensation accounted for $82 thousand and $0.5 million for the three months ended March 31, 2023 and 2022, respectively.

General and administrative expense, as a percentage of total operating expenses for the three months ended March 31, 2023 and 2022 were 13% and 16%, respectively. The percentages, excluding stock-based compensation, for the three months ended March 31, 2023 and 2022, were both 13%.

### Critical Accounting Policies

Our Management’s Discussion and Analysis of Financial Condition and Results of Operations is based on our financial statements, which have been prepared in conformity with generally accepted accounting principles in the United States (US GAAP). The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and expenses incurred during the reported periods.

We base estimates on our historical experience, known trends and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Our significant accounting policies are more fully described in the notes to our financial statements appearing in this Quarterly Report on Form 10-Q.

### Income Taxes

We account for income taxes under the asset and liability method. We record deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which we expect to recover or settle those temporary differences. We recognize the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. We assess the likelihood that deferred tax assets will be realized, and we recognize a valuation allowance if it is more likely than not that some portion of the deferred tax assets will not be realized. This assessment requires judgment as to the likelihood and amounts of future taxable income by tax jurisdiction. To date, with the exception of certain Canada deferred tax assets that will reverse in a period in which they may be carried back, we have provided a valuation allowance against our deferred tax assets as we believe the objective and verifiable evidence of our historical pretax net losses outweighs any positive evidence of our forecasted future results. Although we believe that our tax estimates are reasonable, the ultimate tax determination involves significant judgment. We will continue to monitor the positive and negative evidence and will adjust the valuation allowance as sufficient objective positive evidence becomes available.

We account for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is more likely than not that the position will be sustained upon examination. We recognize potential accrued interest and penalties associated with unrecognized tax positions within our global operations in income tax expense.

### Results of Operations

### Revenue

Revenue during the three months ended March 31, 2023 and 2022 are summarized as follows (in thousands):

| Revenue | Three Months Ended March 31, 2023 | 2022 |
| --- | ---: | ---: |
| Manufacturing revenue | $- | $500 |
| Total revenue | $- | $500 |

Under the clinical manufacturing agreement with Janssen and the addendum, we have recorded $0.5 as manufacturing revenue for the three months ended March 31, 2022. No revenue was recorded in the three months ended March 31, 2023.

### Cost of Goods Sold

Cost of goods sold during the three months ended March 31, 2023 and 2022 are summarized as follows (in thousands):

| Cost of goods sold | Three Months Ended March 31, 2023 | 2022 |
| --- | ---: | ---: |
| Manufacturing cost | $- | $213 |
| Total cost of goods sold | $- | $213 |

The manufacturing cost for the three months ended March 31, 2022 represents cost for quality control department under February 2022 agreement. No cost incurred in the three months ended March 31, 2023.

### Expenses

#### Research and Development

Research and Development costs are summarized as follows (in thousands):

|  | Three Months Ended March 31, 2023 | 2022 | Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Salaries and related expenses | $2,356 | $2,127 | $229 | 11% |
| Laboratory and manufacturing supplies | 967 | 1,701 | (734) | -43% |
| Clinical trials and sponsored research | 479 | 382 | 97 | 25% |
| Stock-based compensation | 623 | 990 | (367) | -37% |
| Other | 1,805 | 1,618 | 187 | 12% |
| Total | $6,230 | $6,818 | $(588) | -9% |

We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates.

Research and development expenses decreased $0.6 million to $6.2 million for the three months ended March 31, 2023, compared to $6.8 million for the three months ended March 31, 2022. The decrease of laboratory and manufacturing suppliers was mainly due to a reduction in raw material purchasing for clinical trial drug manufacturing. The decrease of share-based compensation was due to the stock option expense per share of new grants decreased compared to the expense of fully amortized grants.

#### General and Administrative

General and administrative costs are summarized as follows (in thousands):

|  | Three Months Ended March 31, 2023 | 2022 | Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Salaries and related expenses | $172 | $252 | $(80) | -32% |
| Patent filing expense | 156 | 146 | 10 | 7% |
| Stock-based compensation | 82 | 458 | (376) | -82% |
| Professional fees | 362 | 293 | 69 | 24% |
| Other | 143 | 165 | (22) | -13% |
| Total | $915 | $1,314 | $(399) | -30% |

General and administrative expense decreased $0.4 million to $0.9 million for the three months ended March 31, 2023, compared to $1.3 million for the three months ended March 31, 2022. Both salaies and related expense and stock-based compensation decrease were primary caused by the termination of VP of finance and HR in February 2023. Professional fees increased mainly due to the additional tax service.

### Other income (loss)

The following table summarizes other income (loss) (in thousands):

|  | Three Months Ended March 31, 2023 | 2022 |
| --- | ---: | ---: |
| Interest income | $2,779 | $101 |
| Other income | 130 | - |
| Foreign exchange gain | 383 | 1,290 |
| Total | $3,292 | $1,391 |

The interest income for the three months ended March 31, 2023 and 2022 was mainly from the interest generated from the Company’s Canadian bank account and interest bearing time deposit. Foreign exchange gain for the three months ended March 31, 2023 was mainly due to the liquidation of XBiotech Germany GmbH. Foreign exchange gain for the three months ended March 31, 2023 was caused by the fluctuation between the US dollar and the Canadian dollar in the three months ended March 31, 2022.

### Liquidity and Capital Resources

Our cash requirements could change materially as a result of the progress of our research and development and clinical programs, licensing activities, acquisitions, divestitures or other corporate developments.

Since our inception on March 22, 2005 through March 31, 2023, we have funded our operations principally through private placements and public offerings of equity securities, which have provided aggregate cash proceeds of approximately $118.2 million. We received $675 million in cash proceeds from the Janssen Transaction in the year ended December 31, 2019. In June 2021, we received the remaining $75 million cash as the escrow receivable from the same transaction. In July 2021, we paid $75 million in dividends to shareholders. In July 2022, we purchased interest bearing time deposits in the amount of $63.3 million for a one year term. At March 31, 2023, we had cash and cash equivalents of $152.5 million as compared to cash and cash equivalents of $231.8 million at March 31, 2022. The following table summarizes our sources and uses of cash (in thousands):

| Net cash (used in) provided by: | Three Months Ended March 31, 2023 | 2022 |
| --- | ---: | ---: |
| Operating activities | $(4,808) | $(5,123) |
| Investing activities | (6) | (161) |
| Effect of foreign exchange rate on cash and cash equivalents | (8) | 122 |
| Net change in cash and cash equivalents | $(4,822) | $(5,162) |

During the three months ended March 31, 2023 and 2022, our operating activities used net cash $4.8 million and $5.1 million, respectively. The use of net cash in each of these periods primarily resulted from our net losses. The decrease in net loss from operations for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022 was mainly due to the decrease in laboratory and manufacturing supplies.

During the three months ended March 31, 2023 and 2022, our investing activities used net cash of $6 thousand and $161 thousand, respectively. The decrease was due to costs incurred on fixed asset purchase.

We expect to continue to incur operating losses in the future. We do not expect to receive any additional revenue under the clinical manufacturing agreement with Janssen. Further, we may not receive any product revenue until a drug candidate has been approved by the FDA, EMA or similar regulatory agencies in other countries and successfully commercialized. As of March 31, 2023, our principal sources of liquidity were our cash and cash equivalents, which totaled approximately $152.5 million.

### Off-Balance Sheet Arrangements

Since inception, we have not engaged in any off-balance sheet activities, including the use of structured finance, special purpose entities or variable interest entities.

## Market risk

As filed, 308 characters.

The Company is not currently exposed to material market risk arising from financial instruments, changes in interest rates or commodity prices, or fluctuations in foreign currencies. The Company has no need to hedge against any of the foregoing risks and therefore currently engages in no hedging activities.

## Controls and procedures

As filed, 1,778 characters.

### Management's Evaluation of our Disclosure Controls and Procedures

As of the end of the year covered by this Annual Report on Form 10-Q, an evaluation was carried out by the Company’s management, with the participation of the Chief Executive Officer and Principal Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on such evaluation, the Chief Executive Officer and Principal Financial Officer concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports the Company files or furnishes under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and are operating in an effective manner.

### Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarter ended March 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

### Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Filed May 10, 2023.
Source: SEC EDGAR, the filing index for accession 0001171843-23-003144. Last ingested by Listed: Oct 26, 2026, 09:40 ET. No prices; not investment advice.